<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Relapse of B-lineage <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>) after allogeneic hematopoietic stem cell transplantation (HSCT) commonly results from the failure of a graft-versus-<z:hpo ids='HP_0001909'>leukemia</z:hpo> (GVL) effect to eradicate <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Augmenting the GVL effect by the adoptive transfer of donor-derived <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>-specific T-cell clones is a conceptually attractive strategy to decrease relapse rates without exacerbating <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) </plain></SENT>
<SENT sid="2" pm="."><plain>Toward this end, we investigated whether a genetic engineering approach could render CD8(+) cytotoxic T lymphocytes (CTLs) specific for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells that express the B-cell lineage cell surface molecule CD19 </plain></SENT>
<SENT sid="3" pm="."><plain>This was accomplished by the genetic modification of CTLs to express a chimeric immunoreceptor composed of a CD19-specific single-chain immunoglobulin extracellular targeting domain fused to a CD3-zeta intracellular signaling domain </plain></SENT>
<SENT sid="4" pm="."><plain>CD19-redirected CTL clones display potent CD19-specific lytic activity and chimeric immunoreceptor-regulated cytokine production and proliferation </plain></SENT>
<SENT sid="5" pm="."><plain>Because <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> cells can evade T-cell/natural killer- cell recognition by down-regulation of cell surface accessory molecules that participate in the formation of a functional immunologic synapse, we compared the CD19-specific effector function of genetically modified CD8(+) CTLs toward CD19(+) cells with disparate levels of intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule 1 (ICAM-1), leukocyte function-associated antigen 1 (LFA-1), and LFA-3 </plain></SENT>
<SENT sid="6" pm="."><plain>We observed that recognition of B-lineage <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> lines by CD19-specific CTLs was not impaired by low levels of ICAM-1, LFA-1, and LFA-3 cell surface expression, a functional attribute that is likely a consequence of our high-affinity CD19-specific chimeric immunoreceptor </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, the CD19-specific CTLs could lyse primary <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> blasts </plain></SENT>
<SENT sid="8" pm="."><plain>These preclinical observations form the basis for implementing clinical trials using donor-derived CD19-specific T-cell clones to treat or prevent relapse of <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> after allogeneic HSCT </plain></SENT>
</text></document>